RARECast: Using Cell and Gene Therapies to Treat Rare Skin Diseases
June 26, 2015
Fibrocell Science is developing cell and gene therapy to treat rare skin and connective tissue diseases. The company recently reported encouraging pre-clinical results on its gene therapy for RDEB a congenital, progressive, and debilitating genetic disorder that leads to death. The data sets the stage for Fibrocell and its partner Intrexon to advance the experimental therapy to human clinical trials. We spoke to David Pernock, chairman and CEO of Fibrocell about the company, its cell and gene therapies, and how these technologies promise to bring new approaches to treating devastating diseases.
RARECast is a weekly series by Daniel S. Levine. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013, which produces The Bio Report and RARECast podcasts. Read his full bio here.
Sign up for updates straight to your inbox.